Genentech (DNA) and Biogen (BIIB) Announce Phase III Study of Rituxan(R) Met Primary Endpoint
More News related to BIIB
- Low Investor Sentiment Provides Buying Opportunity in Biogen (BIIB) -BWS Financial
- Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
- Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
- Notable Analyst Rating Changes 11/03: WMT, BIIB, NVDA, SLB Upgraded; SSCC, DO, HAL, PHM Downgraded
- Morning Movers 11/03: VeraSun (VSE) Sinks On Bankrupcty; Goodyear (GT) and Oshkosh (OSK) Up On Results
More News related to DNA
- Bankers Questioning Roche's Ability to Secure $45B Loan to Finance Genentech (DNA) Deal
- IR Global Rankings 2009: Final Registration Deadline Is Today - November 28, 2008
- IR Global Rankings 2009: Registration FINAL Deadline Today
- Genentech (DNA) volatility Elevated at 73
- Genentech (DNA) Announces Phase III Study on Avastin Plus Certain Chemotherapies Meets Primary Endpoints
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) today announced that a global Phase III study of Rituxan(R) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone. There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for U.S. regulatory purposes.
Genentech, Inc. engages in the discovery, development, manufacture, and commercialization of pharmaceutical products in the United States.
Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
